Forty Seven, Acerta Collaborate to Test Triple Combo Therapy on DLBCL Patients
News
Forty Seven and Acerta Pharma are collaborating to test a triple combination of the investigational 5F9 plus Rituxan (rituximab) and Calquence (acalabrutinib) in patients with diffuse large B-cell lymphoma (DLBCL). The partnership builds on ... Read more